These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35980163)

  • 1. Social Vulnerability and Risk of Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation.
    Bhandari R; Teh JB; He T; Nakamura R; Artz AS; Jankowska MM; Forman SJ; Wong FL; Armenian SH
    J Natl Cancer Inst; 2022 Nov; 114(11):1484-1491. PubMed ID: 35980163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
    Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
    Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
    Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
    Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
    Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
    Berro M; Arbelbide JA; Rivas MM; Basquiera AL; Ferini G; Vitriu A; Foncuberta C; Fernandez Escobar N; Requejo A; Milovic V; Yantorno S; Szelagoswki M; Martinez Rolon J; Bentolila G; Garcia JJ; Garcia P; Caeiro G; Castro M; Jaimovich G; Palmer S; Trucco JI; Bet LA; Shaw BE; Kusminsky GD
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1646-1650. PubMed ID: 28669923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation.
    Armenian SH; Xiao M; Berano Teh J; Lee B; Chang HA; Mascarenhas K; Lee S; Iukuridze A; Xie JJ; Scott JM; Jones LW; Lennie Wong F; Forman SJ; Nakamura R
    J Natl Cancer Inst; 2019 Aug; 111(8):837-844. PubMed ID: 30951603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
    Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
    Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT.
    Shouval R; Fein JA; Cho C; Avecilla ST; Ruiz J; Tomas AA; Sanchez-Escamilla M; Flores NC; Yáñez L; Barker JN; Dahi P; Giralt SA; Geyer AI; Gyurkocza B; Jakubowski AA; Lin RJ; O'Reilly RJ; Papadopoulos EB; Politikos I; Ponce DM; Sauter CS; Scordo M; Shaffer B; Shah GL; Sullivan JP; Tamari R; van den Brink MRM; Young JW; Nagler A; Devlin S; Shimoni A; Perales MA
    Blood Adv; 2022 Mar; 6(5):1525-1535. PubMed ID: 34507354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
    Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.
    Veeraputhiran M; Yang L; Sundaram V; Arai S; Lowsky R; Miklos D; Meyer E; Muffly L; Negrin R; Rezvani A; Shizuru J; Weng WK; Johnston L
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1744-1748. PubMed ID: 28668491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.
    Farhadfar N; Dias A; Wang T; Fretham C; Chhabra S; Murthy HS; Broglie L; D'Souza A; Gadalla SM; Gale RP; Hashmi S; Al-Homsi AS; Hildebrandt GC; Hematti P; Rizzieri D; Chee L; Lazarus HM; Bredeson C; Jaimes EA; Beitinjaneh A; Bashey A; Prestidge T; Krem MM; Marks DI; Benoit S; Yared JA; Nishihori T; Olsson RF; Freytes CO; Stadtmauer E; Savani BN; Sorror ML; Ganguly S; Wingard JR; Pasquini M
    Transplant Cell Ther; 2021 May; 27(5):410-422. PubMed ID: 33775617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary function is a strong predictor of 2-year overall survival and non-relapse mortality after allogenic hematopoietic cell transplantation.
    Schierbeck F; Mortensen J; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
    Eur J Haematol; 2023 Jan; 110(1):50-59. PubMed ID: 36153797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
    Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality.
    Shouval R; de Jong CN; Fein J; Broers AEC; Danylesko I; Shimoni A; Reurs MR; Baars AE; van der Schaft N; Nagler A; Cornelissen JJ
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1685-1691. PubMed ID: 29753163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis.
    Blue BJ; Brazauskas R; Chen K; Patel J; Zeidan AM; Steinberg A; Ballen K; Kwok J; Rotz SJ; Perez MAD; Kelkar AH; Ganguly S; Wingard JR; Lad D; Sharma A; Badawy SM; Lazarus HM; Hashem H; Szwajcer D; Knight JM; Bhatt NS; Page K; Beattie S; Arai Y; Liu H; Arnold SD; Freytes CO; Abid MB; Beitinjaneh A; Farhadfar N; Wirk B; Winestone LE; Agrawal V; Preussler JM; Seo S; Hashmi S; Lehmann L; Wood WA; Rangarajan HG; Saber W; Majhail NS
    Transplant Cell Ther; 2023 Nov; 29(11):709.e1-709.e11. PubMed ID: 37482244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Body Composition and Development of Glucose Intolerance after Allogeneic Hematopoietic Cell Transplantation.
    Bhandari R; Teh JB; He T; Peng K; Iukuridze A; Atencio L; Nakamura R; Mostoufi-Moab S; McCormack S; Lee K; Wong FL; Armenian SH
    Cancer Epidemiol Biomarkers Prev; 2022 Nov; 31(11):2004-2010. PubMed ID: 35797113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT.
    Penack O; Peczynski C; Mohty M; Yakoub-Agha I; de la Camara R; Glass B; Duarte RF; Kröger N; Schoemans H; Koenecke C; Peric Z; Basak GW
    Bone Marrow Transplant; 2022 Feb; 57(2):183-190. PubMed ID: 34718346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.
    Rondon-Clavo C; Scordo M; Hilden P; Shah GL; Cho C; Maloy MA; Papadopoulos EB; Jakubowski AA; O'Reilly RJ; Gyurkocza B; Castro-Malaspina H; Tamari R; Shaffer BC; Perales MA; Jaimes EA; Giralt SA
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):2517-2522. PubMed ID: 30055353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.